What is the recommended diagnostic work‑up and treatment for an adult with mediastinal lymphadenopathy suspected to be IgG4‑related disease, including the role of endobronchial ultrasound‑guided transbronchial needle aspiration (EBUS‑TBNA)?

EBUS-TBNA for IgG4-Related Disease with Mediastinal Lymphadenopathy

EBUS-TBNA is an acceptable minimally invasive diagnostic approach for mediastinal lymphadenopathy suspected to be IgG4-related disease, though it has significant limitations for this specific diagnosis and should be performed with awareness that surgical biopsy may ultimately be required for definitive diagnosis.

Diagnostic Approach

Role of EBUS-TBNA in IgG4-Related Disease

While the available guidelines do not specifically address IgG4-related disease, EBUS-TBNA serves as a reasonable first-line diagnostic modality for mediastinal lymphadenopathy of unclear etiology given its established safety profile and diagnostic accuracy of approximately 79% across various benign conditions 1, 2. The American College of Radiology recommends EBUS-TBNA as the first-line diagnostic approach for mediastinal adenopathy requiring tissue diagnosis 2.

Technical Considerations for Optimal Yield

To maximize diagnostic success when performing EBUS-TBNA for suspected IgG4-related disease:

• Perform a minimum of 3 separate needle passes per sampling site when rapid on-site evaluation (ROSE) is unavailable, as sample adequacy reaches 100% after three passes 3, 1
• Use either 21-gauge or 22-gauge needles, both of which are acceptable options per CHEST guidelines 3
• Consider ROSE if available, as it may improve diagnostic yield (78.0% with ROSE versus 71.4% without ROSE) and reduces the number of needle passes required (2.2 vs 3.1 passes, p<0.001) 1
• Request additional tissue beyond cytology samples to allow for histologic architecture assessment and immunohistochemical staining, which are critical for IgG4-related disease diagnosis 3, 4

Critical Limitations for IgG4-Related Disease

The major caveat is that IgG4-related disease diagnosis requires specific histopathologic features and immunohistochemical staining that may be difficult to assess on needle aspiration specimens:

• IgG4-related disease requires demonstration of dense lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis, and elevated IgG4+ plasma cell counts with IgG4+/IgG+ ratio >40%
• EBUS-TBNA primarily yields cytology specimens, which lack the tissue architecture needed for definitive diagnosis 5, 4
• The diagnostic yield may be lower than the 79% pooled accuracy reported for other benign conditions 1

Recommended Diagnostic Algorithm

1. Initial tissue sampling with EBUS-TBNA as the first-line minimally invasive approach 2

   • Perform under moderate or deep sedation 3
   • Sample multiple lymph node stations if enlarged (stations 2L, 2R, 4L, 4R, 7,10-12 are accessible) 6
   • Obtain minimum 3 passes per site 3, 1

2. Coordinate with pathology before the procedure to ensure:

   • Appropriate collection media for immunohistochemistry 1
   • Availability of cell block preparation for histologic assessment 4
   • Capability for IgG4 immunostaining

3. If EBUS-TBNA is non-diagnostic or yields insufficient tissue architecture:

   • Consider mediastinoscopy or video-assisted thoracoscopic surgery (VATS) for excisional lymph node biopsy
   • Surgical biopsy provides larger tissue samples with preserved architecture necessary for definitive IgG4-related disease diagnosis

4. Concurrent evaluation should include:

   • Serum IgG4 levels (though not diagnostic alone)
   • Assessment of other organ involvement (pancreas, salivary glands, kidneys, retroperitoneum)
   • Cross-sectional imaging to characterize extent of disease

Safety Profile

EBUS-TBNA has an excellent safety profile with no reported complications in large series 7, 8, making it appropriate as an initial diagnostic test even when the yield may be suboptimal. The procedure can be performed in the outpatient setting with same-day discharge 6, 7.

Treatment Considerations

Once IgG4-related disease is confirmed (whether by EBUS-TBNA or surgical biopsy), treatment typically involves corticosteroids as first-line therapy, with steroid-sparing agents (rituximab, azathioprine, mycophenolate) for refractory cases or maintenance therapy. However, establishing a definitive tissue diagnosis is critical before initiating immunosuppressive therapy to exclude malignancy and other mimics.